Market revenue in 2024 | USD 87.1 million |
Market revenue in 2030 | USD 116.9 million |
Growth rate | 5.1% (CAGR from 2025 to 2030) |
Largest segment | Salivary stimulants |
Fastest growing segment | Dentifrices |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Salivary Stimulants, Salivary Substitutes, Dentifrices |
Key market players worldwide | GlaxoSmithKline, Church & Dwight Co Inc, Colgate-Palmolive Co, Hikma Pharmaceuticals PLC, Pendopharm, Sun Pharmaceutical Industries, Lupin, Pfizer Inc, Parnell Pharmaceuticals Holdings Ltd, Acacia Pharma |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to xerostomia therapeutics market will help companies and investors design strategic landscapes.
Salivary stimulants was the largest segment with a revenue share of 37.08% in 2024. Horizon Databook has segmented the Japan xerostomia therapeutics market based on salivary stimulants, salivary substitutes, dentifrices covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan xerostomia therapeutics market, including forecasts for subscribers. This country databook contains high-level insights into Japan xerostomia therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account